Vaxcyte Stock - Sunday background on a late-stage vaccine developer
21.06.2026 - 21:06:53 | ad-hoc-news.de
Edited by ad hoc news Background & Management Desk. Verified prior to publication on 06/21/2026, 19:05 UTC. Details in the imprint.
Vaxcyte (US92242T1016) is a clinical-stage vaccine company whose stock is listed on Nasdaq under the ticker PCVX. With no new SEC filings, IR releases or major analyst rating changes reported today, the focus for this Sunday is the company’s background and management setup.
All news and key data on Vaxcyte stock
Background articles, regulatory filings and market data help investors follow how Vaxcyte develops its vaccine pipeline and how the stock trades on Nasdaq.
Background on Vaxcyte’s business
Vaxcyte is developing next-generation conjugate and protein-based vaccines using a cell-free protein synthesis and conjugation platform designed to efficiently produce complex antigens. The company’s pipeline currently centers on pneumococcal disease prevention in adults and children.
Its lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine being studied in adult indications and designed to broaden coverage against Streptococcus pneumoniae strains compared with existing vaccines. Additional candidates include VAX-31, a 31-valent PCV program, and earlier-stage vaccines targeting other bacterial pathogens.
Management, funding and listing overview
Vaxcyte is headquartered in San Carlos, California, and is led by co-founder and chief executive officer Grant Pickering, who has decades of experience in vaccine development and biotech leadership roles. The company’s board includes industry and financial executives from the biopharma sector.
The company listed on Nasdaq under the ticker PCVX in 2020, raising capital to fund clinical development of VAX-24 and its broader vaccine platform. Since then, Vaxcyte has conducted follow-on offerings to strengthen its balance sheet and support late-stage trials.
How the company makes money in future
As a clinical-stage biotech, Vaxcyte currently generates no commercial product revenue and funds operations primarily through equity financings and potentially partnership payments. The long-term business model relies on bringing VAX-24 and follow-on vaccines to market and earning sales-based income and potential royalties.
Where the stock trades today
The shares of Vaxcyte (US92242T1016) trade on Nasdaq at $51.44 as of 06/18/2026, 16:00 ET, based on the latest available closing data.
Key facts on Vaxcyte stock
- Company: Vaxcyte Inc.
- ISIN: US92242T1016
- WKN: A2QK2R
- Ticker: PCVX
- Venue: Nasdaq
- Price (as of 06/18/2026, 16:00 ET): 51.44 USD
- Market cap: 6.0 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: not a member of major headline indices such as the S&P 500 or Nasdaq-100
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
